Showing 4 posts of 4 posts found.


Reaction mixed to Biohaven’s migraine drug results

March 27, 2018
Manufacturing and Production, Research and Development Allergan, Biohaven, CGRP, biotech, drugs, migraine, pharma, pharmaceutical

Biohaven is full of confidence in its lead drug, rimegepant, evidenced only a few weeks ago when it decided to …


Migraine drug bad news hits a weakened Teva

February 9, 2018
Medical Communications, Sales and Marketing CGRP, Teva, biotech, drugs, pharma, pharmaceutical

The cacophony of bad news that Teva has received in 2017 really needs no retelling, anyone following the story of …


New breakthrough for CGRP migraine treatments

February 6, 2018
Research and Development Allergan, Amgen, CGRP, Novartis, biotech, drugs, pharma, pharmaceutical

Allergan had a rough year in 2017, dropping by close to $80 a share from February 2017 to this month. …


Novartis’ Phase 3 migraine data could revolutionise treatment

November 30, 2017
Research and Development CGRP, Novartis Amgen, biotech, drugs, migraine, pharma, pharmaceutical

Descriptions of treatments as ‘revolutionary’ or ‘ground-breaking’ are ten a penny in the pharmaceutical industry, very rarely do such treatments …

Latest content